Coherus Oncology, Inc. (CHRS)
| Market Cap | 242.17M +99.0% |
| Revenue (ttm) | 46.88M +48.0% |
| Net Income | 186.27M |
| EPS | 1.52 |
| Shares Out | 154.25M |
| PE Ratio | 1.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,507,747 |
| Open | 1.610 |
| Previous Close | 1.630 |
| Day's Range | 1.555 - 1.645 |
| 52-Week Range | 0.710 - 2.616 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+345.86%) |
| Earnings Date | May 11, 2026 |
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo... [Read more]
Financial Performance
In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 345.86% from the latest price.
News
Coherus Oncology reports Q1 EPS (28c), consensus (26c)
Reports Q1 revenue $12.31M, consensus $14.34M. “We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination wit...
Coherus Oncology Earnings Call Transcript: Q1 2026
LOQTORZI sales rose 61% year-over-year, with new patient starts at a record high despite Q1 weather disruptions. The pipeline advanced with key clinical milestones, and a $54M equity raise strengthened funding for ongoing trials and commercialization.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projectio...
Guggenheim starts Coherus with Buy on anti-tumor potential
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target Coherus recently completed a transformation from a biosimilars platform to a pure-play immuno-oncology c...
Coherus Oncology initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monda...
Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026
The company has transformed into a focused oncology innovator, advancing LOQTORZI, tagmokitug, and casdozokitug across multiple cancer indications. Strong sales growth, strategic collaborations, and promising clinical data position it for significant market expansion and pivotal trial decisions in 2026.
Coherus Oncology reports Q4 EPS (34c), consensus (31c)
Reports Q4 revenue $12.75M, consensus $14.09M. “We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative ...
Coherus Oncology Earnings Call Transcript: Q4 2025
Transformation to a focused oncology company drove LOQTORZI sales up 113% year-over-year, with debt reduced by over 90%. Multiple clinical trials for tagmokitug and casdozokitug are underway, with key data readouts expected from mid-2026.
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172...
Options Volatility and Implied Earnings Moves Today, March 09, 2026
Today, several major companies are expected to report earnings: 3D Systems (DDD), Casey’s General (CASY), Coherus Biosciences (CHRS), Fuelcell Energy (FCEL), W&T Offshore (WTI), Zevra Therapeutics (ZV...
Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Management highlighted a successful transformation to oncology, major debt reduction, and strong commercial momentum for LOQTORZI. Pipeline assets tagmokitug and casdozokitug show promising clinical data and broad partnering opportunities, with key data readouts expected mid-year.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after mark...
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations w...
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–
Coherus Oncology 28.6M share Spot Secondary priced at $1.75
TD Cowen, Guggenheim and Oppenheimer acted as joint book running managers for the offering.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000...
Coherus Oncology announces common stock offering, no amount given
Coherus Oncology (CHRS) announced a proposed underwritten public offering of its common stock. All of the shares in the offering are being offered by Coherus. Coherus intends to use the…
Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts
As previously reported, Oppenheimer analyst Jay Olson initiated coverage of Coherus Oncology (CHRS) with an Outperform rating and $10 price target citing upcoming clinical readouts in 2026 across mult...
Coherus Oncology initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Coherus Oncology (CHRS) with an Outperform rating and $10 price target
Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a strategic transformation, with major divestitures funding a robust oncology pipeline. LOQTORZI sales are exceeding targets, while tegmokitug and casdozokitug show strong clinical promise, with pivotal data readouts expected in 2026.
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference o...
Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug
Coherus Oncology (CHRS) announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and signif...
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical s...
Coherus Oncology Transcript: Biotech Discovery Series
The event highlighted a strategic pivot to immuno-oncology, with promising data for Casdozokitug in HCC and Tagmokitug in multiple solid tumors. Key 2026 data readouts are expected, and Toripalimab continues to show strong survival benefits and commercial progress.